Background {#Sec1}
==========

Dyslipidemia is one of the common problems in children and adolescents. This condition is defined as disorders of triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). The non-HDL-C, which encompasses all atherogenic cholesterols suggested as a novel predictor of cardiovascular diseases (CVDs) which has been linked to some indicators of metabolic syndrome in adolescents \[[@CR1]\].

Dyslipidemia can be developed in childhood and might lead to atherosclerotic lesions in adulthood \[[@CR2]\] such as increased intima-media thickness \[[@CR3]\]. Genetic form of hypercholesterolemia or familial hypercholesterolemia (FH) is also an important issue in children as it can increase risk of CVDs later in life \[[@CR4]\]. This disorder has two forms characterized by very high levels of LDL-C. Heterozygous form of FH is more prevalent and results in atherosclerotic signs like increased carotid intima-media thickness from childhood \[[@CR5]\]. Homozygous FH is also related to premature atherosclerotic CVDs and early death in children \[[@CR6]\]. Although homozygous form of FH is rare, but it is associated with extremely high risk of CVDs. Its early detection and treatment can reduce the risk of cardiovascular events. Hence, the diagnosis of dyslipidemia is an important health issue in children and adolescents.

Lipid levels change during different periods of childhood and are affected by gender and ethnicity; therefore, lipid abnormalities in the pediatric age group should be identified based on the percentile thresholds. According to the guidelines of the National Cholesterol Education Program (NCEP) and the Bogalusa Heart Study, TC, LDL-C, non-HDL-C, and TG values of \>75th percentile are considered as borderline. Furthermore, values of \>95th percentile for the aforementioned parameters and \< 10th percentile for HDL-C are considered as abnormal \[[@CR3], [@CR7]\]. It was previously recommended to screen dyslipidemia in children ≥2 years old who have a first or second -degree relative (males \< 55 and females \< 65 years old) with confirmed CVDs or those with established risk factors of CVDs such as overweight, diabetes, hypertension, smoking, unhealthy diet, and inactivity \[[@CR8]\]. According to the American Heart Association Statement published in 2019, identification and treatment of CVD in youth should be initiated by defining the risk level \[[@CR9]\]. This process is based on the existence of the following factors: children with traditional CVD risk factors including FH, as well as childhood cancer, endocrine and renal diseases, inflammatory disorders, underlying heart disease, and non-communicable diseases. Thus, the risk assessment should be done by evaluating the lipid and glucose profile, smoking status, family history of premature CVD, as well as levels of BP, BMI, and physical activity.

A systematic review in 2015 showed relatively high prevalence of dyslipidemia among Iranian children and adolescents \[[@CR10]\]. Hence, it is of particular importance for healthcare professionals to identify children at risk of atherosclerosis and release of guidelines for controlling and preventing CVDs in the future.

Studies in different populations and ethnic groups have revealed variable cholesterol concentrations \[[@CR11]\]. It is reported that whites have higher levels of very low density lipoprotein cholesterol (VLDL-C) and TG, as well as, slightly lower HDL-C levels compared with blacks \[[@CR12]\]. The differences in factors like body fat distribution, activity of enzymes involved in lipid hydrolysis, insulin response, and some specific apolipoproteins can partly explain the interethnic differences in serum lipids \[[@CR13]\]. Many countries use the NCEP pediatric cutpoints for screening the lipid disorders without consideration of possible ethnic differences. Therefore, the diagnostic criteria of dyslipidemia and reference values of lipid parameters should be refined based on the nationality, ethnicity, as well as the age and sex of individuals. This is especially important among children and adolescents. In the present study, we aimed to develop the age- and sex-specific reference values for serum lipid parameters in a representative population of Iranian children and adolescents.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The Ethics Committee of the Isfahan University of Medical Sciences approved this study. Verbal and written informed consents were obtained from all participants and their parents, respectively. The data was extracted from the fifth survey of a surveillance program entitled Childhood and Adolescence Surveillance and Prevention of Adult Non communicable disease (CASPIAN-V). It was conducted as a nationwide study on a representative sample population of urban and rural Iranian children with 7--18 years of age, who lived in 30 provinces across the country. Details of this study is published elsewhere \[[@CR14]\].

Lipid profiles (TG, TC, LDL-C, HDL-C, and non-HDL-C) of 3843 children were obtained. Children and adolescents with history of any underlying health problem or chronic medication use were not included in the study.

Measurements {#Sec4}
------------

Venous blood samples were obtained from all the subjects between 7 and 9 A.M and following overnight fasting. The collected samples were centrifuged and frozen at − 70 °C. Serum lipid parameters including TC, LDL-C, HDL-C, and TG were measured by an enzymatic method colorimetric method using an automated analyzer (Hitachi Automatic Analyzer 7600, Hitachi). LDL-C was measured directly. Firstly, we used cholesterol esterase and cholesterol oxidase to produce H2O2, which was consumed by catalase in the presence of 4-aminoantipyrene. Then, N, N-bis-(4-sulfobutyl)-mtoluidine disodium salt, buffer, and a detergent were added to release cholesterol from LDL-C and a colored product that is proportional to LDL-C concentration. Non-HDL-C was calculated as "TC- HDL-C".

Statistical analysis {#Sec5}
--------------------

Continuous and categorical variables were expressed as mean (standard deviation, SD) and number (%), respectively. The mean values of continuous variables were compared between genders using independent samples Student t test. A parametric method was used to define the age-specific reference values by obtaining smooth centile curves and explicit formulae for the centile estimates and SD scores (age-sex standardized values). Each parameter of exponential-normal or modulus-exponential-normal density was modeled as a fractional polynomial function of age. The estimation was based on the maximum likelihood. These three- and four-parameter models transformed the data to attain normal distribution and remove skewness and/or kurtosis. Fractional polynomials provide more flexible curves than those of conventional polynomials. Goodness of fit was assessed using Q-Q plots and Shapiro-Wilk W-test of the SD scores. Likelihood ratio test was applied as an enlarged model.

Results {#Sec6}
=======
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The mean value of TC was 153.02 (26.87) mg/dL in boys and 154.93 (25.87) mg/dL in girls (*P* = 0.02). TC showed a decreasing trend at all percentiles and all age groups among boys. In girls, TC levels also increased with age at all percentiles except for the 75th and 90th percentiles (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Reference percentile curves for TC according to age in Iranian boys (**a**) and girls (**b**)

The overall mean value of LDL-C was 89.21 (21.91) mg/dL in boys and 90.88 (21.71) mg/dL in girls with a significant gender difference (*P* = 0.01). The overall mean value of HDL-C was 46.14 (9.89) mg/dL in boys and 46.11 (9.68) mg/dL in girls without significant gender difference (*P* = 0.92). Among boys, the levels of LDL-C and HDL-C decreased with age in all percentiles. However, LDL-C and HDL-C concentrations increased up to the 50th in girls and then decreased with age (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). Fig. 3Reference percentile curves for LDL-C according to age in Iranian boys (**a**) and girls (**b**)Fig. 4Reference percentile curves for HDL-C according to age in Iranian boys (**a**) and girls (**b**)

The overall mean value of non-HDL-C was 106.62 (24.69) mg/dL in boys and 108.89 (23.34) mg/dL in girls with a significant gender difference (*P* = 0.03). The non-HDL-C also decreased in the 50th and higher percentiles among boys and in the 90th and 95th percentiles among girls (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Reference percentile curves for non-HDL-C according to age in Iranian boys (**a**) and girls (**b**)

The overall mean value of the TG/HDL-C ratio was 1.97 (1.11) mg/dL in boys and 2.03 (1.19) mg/dL in girls without significant gender difference (*P* = 0.10). The TG/HDL-C ratio increased with age at all percentiles in boys. In girls, TG/HDL-C ratio increased with age in the 50th and higher percentiles (Fig. [6](#Fig6){ref-type="fig"}). Fig. 6Reference percentile curves for the TG/non-HDL-C according to age in Iranian boys (**a**) and girls (**b**)

Discussion {#Sec7}
==========

Our study provides reference values for serum lipid profiles in a nationally representative sample of Iranian pediatric population. In general, girls had higher levels of serum TG, TC, LDL-C, and non-HDL-C compared with boys. TG and TG/HDL-C ratio increased with age in both genders. As well, TC level increased with age in girls; whereas, HDL-C and non-HDL-C levels of both genders and TC in boys decreased with age.

Based on the reference values of lipid parameters released by the NCEP Expert Panel on Cholesterol Levels in Children, the following thresholds have been considered to define pediatric dyslipidemia: TC ≥ 200 mg/dL, LDL-C ≥ 130 mg/dL, HDL-C \< 40 mg/dL, and non-HDL-C ≥ 145 mg/dL. Furthermore, the recommended thresholds for defining hypertriglyceridemia have been ≥100 mg/dL and ≥ 130 mg/dL in children aged 0--9 and 10--19 years, respectively \[[@CR15]\]. In the present study, the 95th percentiles for TC and LDL-C concentrations were close to the values recommended by the NCEP. However, non-HDL-C level was slightly higher in present report. Furthermore, the 95th percentile of HDL-C was markedly lower, and that of TG was remarkably higher in the present study compared with the NCEP values. Variability in genetic background and different dietary habits can justify these differences.

Results of the current study demonstrated some gender differences in the reference values of serum lipid among children and adolescents. The pathophysiology, diagnosis and treatment of dyslipidemia in adults are different based on gender \[[@CR16]\]. Moreover, several studies have reported gender differences in the levels of serum lipid parameters in children. A study on 1000 Indian students showed that boys had higher TC, LDL-C, and HDL-C and lower TG levels compared with girls \[[@CR17]\]. A study on 2283 children and adolescents, aged 7--18 years, living in urban and rural areas of China revealed higher prevalence of elevated TC and LDL-C in girls than in boys. Furthermore, girls had higher mean values of HDL-C in comparison with boys \[[@CR18]\]. Brazilian girls had also higher concentrations of TC and LDL-C compared with boys \[[@CR19]\]. These variations may be in part due to the physiological and hormonal differences between boys and girls.

In line with other studies, we here found that some lipids parameters increased with age. In this regard, TG and TG/HDL-C in both genders and TC in girls increased with age in our study. In a study in Korean children, TG/HDL-C ratio increased with age in boys and decreased with age in girls \[[@CR20]\]. In another study on 2141 Danish/North-European children and adolescents aged 6--19 years old, non-HDL-C levels decreased with age in boys \[[@CR21]\]. In a longitudinal study on 633 children aged 8--18 years old, TC, LDL-C, and non-HDL-C levels in both genders and HDL-C in boys also increased with age. Moreover, TG level showed an increasing trend in boys during puberty \[[@CR22]\].

Taking together, it is recommended to define the age and sex specific thresholds for evaluating lipid profile in the pediatric age group, especially among children and adolescents who are at risk of CVDs. In addition, it should be considered that factors such as ethnicity, nationality, dietary regimen, physical activity, hormonal status, environmental factors, and socioeconomic status can influence lipid profile in children \[[@CR20], [@CR23]\]. Therefore, establishing national references for lipid parameters should be encouraged.

This study has several strengths. To the best of our knowledge, this survey is one of the few efforts to establish reference values for lipid parameters in a large population-based sample of children and adolescents in the Eastern Mediterranean region; our sample was nationally- representative; and blood samples were drawn in fasting state. There are also some limitations. Our data was obtained based on a cross-sectional study; moreover we were not able to evaluate the impact of pubertal stage on lipid changes.

Conclusion {#Sec8}
==========

This study showed different thresholds for lipid parameters in Iranian children and adolescents in comparison with those presented by the NCEP. We also observed some differences in the reference values between genders and among age groups. Since early detection of lipid disorders in children and adolescents using reference values from other nations and ethnicities may not be correctly performed, our results could provide nation-specific cutpoints for screening and interpretation of lipid abnormalities in Iranian pediatric population. However, further investigations should be conducted for defining optimal cutpoints to perform successful interventions and strategies to manage dyslipidemia in the pediatric age group.
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